Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A known ✓ | P37088 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 7/20 | 0.49 |
| ▸ | GLA | P06280 | 7/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | THPO | P40225 | 3/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiloride SCHEMBL29129215 | 0.97 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL317394 | 0.95 | SCNN1A (0.56) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL1487484 | 0.95 | SCNN1A (0.56) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL15517241 | 0.95 | SCNN1A (0.58) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL27562 | 0.95 | SCNN1A (0.58) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL1441814 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL17986365 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL21524891 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL3253482 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL41233 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2147 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-222544246-U | Hot air circulation oven for amiloride hydrochloride production | 江苏迪赛诺制药有限公司 | 2025-02-28 | — | — | CN | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| US-11559524-B2 | Composition for reducing nervous system injury and method of making and use thereof | MOREHOUSE SCHOOL OF MEDICINE (US) | 2023-01-24 | — | — | US | claimed |
| US-20230017661-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2023-01-19 | — | — | US | claimed |
| EP-3955954-A1 | COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | NGM Biopharmaceuticals, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| US-11065205-B2 | Immediate/delayed drug delivery | DRUG DELIVERY INTERNATIONAL LIMITED (GB) | 2021-07-20 | — | — | US | claimed |
| WO-2021119464-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2021-06-17 | — | — | WO | claimed |
| US-10940151-B2 | Methods for treating renal disease | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-03-09 | — | — | US | claimed |
| US-20200390858-A1 | Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases | NGM BIOPHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | claimed |
| EP-3737676-A1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | Ligand Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | claimed |
| US-6720001-B2 | EMULSION COMPRISING: (A) AN AQUEOUS PHASE; (B) AN OIL PHASE COMPRISING A STRUCTURED TRIGLYCERIDE; AND (C) AN EMULSIFIER. | LIPOCINE, INC. | 2004-04-13 | — | — | US | claimed |
| US-20030064097-A1 | For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents | LIPOCINE INC. | 2003-04-03 | — | — | US | claimed |
| EP-1233756-A1 | SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS | Lipocine, Inc. (US) | 2002-08-28 | — | — | EP | claimed |
| US-20020107265-A1 | EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS | LIPOCINE INC. | 2002-08-08 | — | — | US | claimed |
| EP-1210063-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | Lipocine, Inc. (US) | 2002-06-05 | — | — | EP | claimed |
| US-6309663-B1 | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents | LIPOCINE INC. | 2001-10-30 | — | — | US | claimed |
| US-6248363-B1 | Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents | LIPOCINE, INC. | 2001-06-19 | — | — | US | claimed |
| WO-2001037808-A1 | SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS | LIPOCINE, INC. (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001028555-A1 | EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS | LIPOCINE, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2001012155-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2001-02-22 | — | — | WO | claimed |